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In the process of designing new drug molecules, permeation 
of drugs through the Blood Brain Barrier (BBB) is 
elementary for the antipsychotics to interact with the 
specific site of action inside the Central nervous system 
(CNS). The BBB is composed of distinctly specialised 
microvascular endothelial cells along with astrocytes, 
neurons, pericytes, microglia and basement membrane
 1,2
. 
The endothelial capillary cells are interconnected by 
claudins, occludins (proteins) and adhesion molecules 
resulting in tight junctions, which shut the intercellular 
space, thus limiting the permeability of many CNS active 
molecules
3,4
However large number of molecules can enter 
the Central nervous system(CNS) through transcellular 
passive diffusion, resulting due to concentration gradient 
between brain and blood
5
. Off the available drugs, only 2% 
are able to cross the BBB especially antipsychotics. Drugs 
due to their physiological and molecular properties, polar 
surface area, hydrophilicity, hydrophilicity, molecular 
charge and size can easily cross the BBB, hence BBB 
permeability for the prospective drug molecules at different 
conditions would be of paramount importance in the design 
and development of these molecules as drugs
6
. In the 
present study we are assessing the Blood Brain Barrier 







piperidine-1-carbothiamide (S2), 4-(6-fluorobenzo[d] 
isoxazole-3-yl)-N-(2-fluorophenyl)) piperidine-1-
carbothiamide (S3), N-(4-chlorophenyl)-4-(6-fluorobenz [d] 
isoxazole-3-yl) piperidine-1-carbothiamide (S4) along with 
the standard antipsychotic drugs Haloperidol and 
Resperidone , through in vitro and in silico methods. All the 
above molecules in our earlier studies have satisfied 
Lipinski`s rule of five parameters suggesting that they are 
orally bioavailable, non-toxicity, and indicated significant 
bioactive scores, thus making them suitable candidates for 
further investigation as potential Antipsychotic drugs, in 
this regard BBB permeability studies is an very important 
and essential criteria for the molecules to qualify for further 
antipsychotic studies. Hence in vitro screening of the 
molecules was conducted using Parallel artificial membrane 
permeability assay (PAMPA) in PBS and in silico screening 
was done using rodent model. 
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ABSTRACT  
Blood Brian Barrier (BBB) is a physiologically and metabolically significant membrane that enables and limits the uptake of 
specific molecules by the brain, thus preserving the homeostasis within the Central nervous System (CNS).All the 
Antipsychotic drugs are permeable across the BBB, however most of First/Second generation antipsychotic drugs employed in 
the medical field are known to be associated with Extrapyramidal symptoms (EPS). Hence our interest is devoted in the 
development of novel antipsychotic drugs that ameliorate psychosis with least frequency of EPS. In our previous study the 
newly synthesized molecules, 6-fluoro-3-(piperidin-4-yl) benzo[d]isoxazole derivatives (S1-S4) which have shown positive 
alterations in chemical properties and biological activities demonstrating significant neuroleptic properties. However 
possibility and efficiency of these synthesized molecules to penetrate through the Blood Brain Barrier will be of utmost 
importance to determine its treatment efficacy. In this line of investigation, in the present study, in silico and in vitro methods 
are employed to evaluate the permeability in comparison with that of standard antipsychotic drugs, Resperidone and 
Haloperidol. In vitro analysis was done by Parallel artificial Membrane Permeability Assay (PAMPA) in PBS, where in 
permeability of S2(8.3x10-6) and S3(6.6x10-6) molecules showed higher permeability than known standards Warfarin(1x10-6), 
Resperidone(2.3x10-6) and Haloperidol(3.5x10-6), and the molecules exhibited recovery above 50% and in silico studies also 
showed high permeability rate with all the synthesized molecules. Thus we can conclude that, all the synthesized molecules 
have the potential to develop into promising Antipsychotic drugs. 
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MATERIAL AND METHODS 
Materials 
All the chemicals were procured form Fluka, Merck and 
Sigma Aldrich. Permeability assay was performed in 
Phosphate buffer (PBS, K2HPO4 and KH2PO4, pH 7) in 
Multiscreen Millipore TM, plate and PTFE acceptor 
plate. L-α-Phosphatidylcholine, and Dimethyl Sulfoxide 
was purchased from (Sigma,USA) and Dodecane was 
purchased from (Fluka,India) The entire reagents used in 
the investigation were of analytical grade. The drug 
analysis was done on LC-MS/MS (AB Sciex Triple 
Quad 5500).  
Methods 
PAMPA Assay: The experiment was performed in a 96 
well sandwich plate, according to Schmidt and Lynch
8
 
with slight modifications. 1% lecithin solution (w/v) was 
prepared in dodecane (~500 µL/plate) and the mixture 
was sonicated to ensure complete dissolution. Then 5 µL 
of Lecithin/dodecane mixture was carefully spiked into 
each donor plate well with the help of a 10 µL 
adjustable-volume pipette, avoiding pipette tip contact 
with the membrane. Immediately after the application of 
the artificial membrane (within 10 min maximum), 150 
µL of 50 µM drug containing donor solutions (drug 
dissolved in PBS) was added to each well of the donor 
plate. 300 µL of aqueous buffer was added to each well 
of the acceptor plate. Slowly and carefully the drug filled 
donor plate was placed into the acceptor, making sure 
that the underside of the membrane is in contact with the 
buffer in all wells. Finally the lid was replaced and 
incubated at room temperature for 16h.The samples were 
than analysed on LC-MS/MS (AB Sciex Triple Quad 
5500) with gradient elution mobile phase 
(Acetinitril:0.2% Formic acid in water) with a flow of 
0.85mL/min, 2 µL wer injected with a total run time of 
4.5 min using the column Atlantis C18 (50 x 4.6 mm, 3 
µm-Waters, Ireland).  
Permeability calculations: The apparent permeability 
Co-efficient (Papp) for the Uni-transport direction (A to 
B) was calculated 
[9]
 according to the following equation: 
Papp = (∆Q
~∆t) ~ (AxCD) [cm/s] 
Where (∆Q~∆t) [cm/s] is the cumulative amount of test 
compound transported overtime, A is the surface area of 
the monolayer membrane (cm
2
) and CD is the average 
drug concentration in the donor chamber over the period 
(∆Q~∆t) was determined. 
Recovery during the experiment was calculated as: 
Recovery [%] = [(QDend + QRend)
~ 
QD0] x 100 
Where (QDend + QRend) is the final amount of the 
compound found in both donor and receiver sides and 
QD0min is the amount in the donor side at start (0 min). 
Computational studies: All computational studies were 
carried in the ACD/ILAB property predictions. BBB 
parameters such as Rate of Brain penetration (logPS), 
Extent of Brain penetration (logPB), Brain Plasma 
equilibrium constant (log PS
* 
fu, brain) and LogBB were 
measured in silico. 
RESULTS AND DISCUSSION  
In the present study Apparent permeability (Papp) and 
Recovery % of the synthesized 6-fluoro-3-(piperidin-4-
yl) benzo[d]isoxazole derivatives (S1-S4), Standards 
Warfarin, Propranolol HCl and standard Antipsychotic 
drugs Haloperidol and Resperidone were determined by 
PAMPA studies. 
 
Table 1: Apparent permeability (Papp) and Recovery % values of S1-S4, Warfarin, Propranolol HCl, Haloperidol and 
Resperidone determined through PAMPA studies. 
COMPOUND A→B(10-6 cm/sec) RECOVERY[%] 
Warfarin  1 62 
Propranolol HCl 3.6 76 
Haloperidol 3.2 72 
Resperidone 4.4 81 
S1 1.4 65 
S2 8.3 79 
S3 6.6 77 
S4 0.8 59 
  
The Apparent permeability (Papp) values for any 
molecule to be considered permeable across BBB will be 
compared to  following criteria :< 1 x 10
-6 
cm/sec 
indicates low permeability; 1 to 3 x 10
-6 
cm/sec indicates 
medium permeability and > 3 x 10
-6 
cm/sec indicates 
high permeability. In Table 1,  Papp  values of the 
molecules are recorded and the S2 and S3 molecules 
showed high permeability with 8.3 x 10
-6 
cm/sec and 6.6 
x 10
-6 
cm/sec respectively which  is found to be much 
higher than normally used standard compounds 
Propranolol HCl (3.6 x 10
-6 
cm/sec) and Warfarin (1 x 
10
-6 
cm/sec). The values obtained for S2 and S3 is also 
significant as they also exhibited Papp values much higher 
than antipsychotic drugs Haloperidol (3.2 x 10
-6 
cm/sec) 
and resperidone (4.4 x 10
-6 
cm/sec). However Papp values 
of S1 (1.4 x 10
-6 
cm/sec) and S4 (0.8 x 10
-6 
cm/sec) were 
medium and low.  The percentage of the administered 
drug that is actually penetrating the Blood Brain Barrier 
(BBB) 
10
 is another important factor when considering 
the interaction potentials of Antipsychotics within the 
Central nervous system (CNS) is. Thus recovery % 
across the membrane, of the above molecules assumes a 
significant factor. From the above table it is clear that the 
synthesized molecules S2 (79%) and S3 (77%) almost 
have very similar values that of Haloperidol (72%) and 
Resperidone (81%), predicting the positive intactness of 
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the molecules. Even S1 (65%) and S4 (59%) showed 
almost similar values like that of standard Warfarin 
(62%). The above results clearly indicated that the 
synthesized molecules have very good permeability like 
that of the established antipsychotic drugs and standard 
compounds.
 
In silico permeability predictions: 
Table 2: Blood Brain Barrier permeability predictions of S1-S4, standard compounds, Haloperidol and Resperidone 
COMPOUND LogPS LogPB Log 
(PS*fu, brain) 
LogBB 
Haloperidol -1.5 0.47 -2.9 0.61 
Resperidone -1.6 0.48 -3 0.57 
S1 -1.7 0.16 -3.2 0.42 
S2 -1.2 0.56 -3.2 0.58 
S3 -1.1 0.46 -3.2 0.49 
S4 -1.6 0.51 -3.1 0.44 
 
The information given in the Table 2 provides a 
comprehensive assessment of the permeation potential of 
candidate molecules based on their passive transport 
across the BBB. From the above Table 2 it is clearly 
evident that extent of brain penetration determined by 
ratio of total drug concentrations in tissue to the plasma 
at steady-state conditions (LogBB values) indicate 
11
 
very high values for Haloperidol (0.61), resperidone 
(0.57) and S2 (0.58) molecules, even the other molecules 
S1, S3, S4 also showed high values indicating good BBB 
permeation. Rate of Brain penetration (LogPS) values for 
the standard antipsychotic drugs and the synthesized test 
molecules did not show significant difference and it 
ranged from -1.1 to -1.7. LogPB (extent of Brain 
penetration) values were remarkably and high for the 
molecules S2 (0.56) and S4 (0.51), which was higher 
than the standard antipsychotics Haloperidol (0.47) and 
Resperidone (0.48). High values were also recorded for 
S3 (0.46), but a comparatively lesser value was seen with 
S1 (0.16) molecule. Brain/plasma equilibration rate [Log 
(PS*fu, brain)] for all the molecules tested ranged from -
2.9 to -3.2 indicating permeability potentials of the test 
compounds are similar to that of standard drugs. From 
the above findings it is obvious that the synthesized 
fluoro-3-(piperidin-4-yl) benzo[d]isoxazole derivatives 
(S1-S4) have shown very promising results like that of 
standard antipsychotic drugs. 
 
 
            
                 Haloperidol       Resperidone      
                                                                       
             
 S1 S2 
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 S3 S4 
In the above graphs compounds in the green represent CNS activity of the respective molecules 
CONCLUSION 
The in vitro and in silico studies have indicated that the 
synthesized molecules (S1-S4) have very high Blood 
Brain Barrier (BBB) permeability. The comparison of 
the results with the standard antipsychotics Haloperidol 
and Resperidone reveal that the values are very 
significant and encouraging. PAMPA studies, Log PB 
and Log BB values were higher or similar to the 
standards concludes by itself that the synthesized 
molecules may be potential antipsychotic drug 
candidates. Thus it can be concluded that fluoro-3-
(piperidin-4-yl) benzo[d]isoxazole derivatives (S1-S4) 
can be investigated further for its Antipsychotic 
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